Concepedia

Wanning Xu

WX

Statistics

Publications

1

Citations

14

H-Index

1

Active since

2022

Affiliations

Dana-Farber Cancer Institute(Current)

Wanning Xu is an author at Dana-Farber Cancer Institute specializing in medicine, cancer cell biology, and pathology.

Top concepts

UrologyMedicineOncologyPathologyPharmacologyTumor BiologyCancer TherapyCancer ResearchMolecular OncologyRadiation Oncology

Publications per year

2022–2022

1

Publications

1

SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC).

Toni K. Choueiri, Wanning Xu, Lynne Poole et al. · Journal of Clinical Oncology · 2022 · 14 citations

Pathology, Tumor Biology, Oncology +17

1–1 of 1